William Parker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William Parker has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
Mary Lou Everett
A Department of Surgery , Duke University Medical Center , Durham , North Carolina , USA
10 shared publications- Zacharoula Konsoula
WPLab, USA
10 shared publications - John P. Jones Iii
WPLab, USA
9 shared publications Zoie E. Holzknecht
Department of Surgery, Duke University School of Medicine, Durham, NC, USA
8 shared publicationsShu S. Lin
Departments of Surgery, Duke University Medical Center, Durham, NC USA
7 shared publicationsAntara Palkar
Surgery Durham NC 27710 Duke University Medical Center
6 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Elsevier in SSRN Electronic Journal
Vulnerability of the Neonatal Rat Brain to Sub-Hepatotoxic Doses of Acetaminophen and Evidence for Fetal Protection
Numerous studies in laboratory animal models have demonstrated that exposure to acetaminophen in utero or in the first days of life leads to long-term alterations in behavior. However, it remains unknown whether acetaminophen metabolism affects the developing brain. Acetaminophen metabolism is characterized by formation of the toxic metabolite, N-acetyl-p-benzoquinone imine, which binds covalently to cysteine residues, forming an adduct and leading to toxicity. In this study, laboratory rats were exposed to 4 doses of acetaminophen over a 2-day period, and tissues were examined two hours following the final exposure. Acetaminophen-Cys adducts were formed in a dose-dependent fashion in the brain of neonatal rats (postnatal days 4 and 5) exposed to 30 mg/kg, 60 mg/kg, and 150 mg/kg acetaminophen. Based on immunohistochemical assessment of cleaved caspase-3 and the formation of pyknotic bodies, higher levels of cell death in the prefrontal cortex and the nucleus accumbens were observed in neonates treated with 60 mg/kg and 150 mg/kg acetaminophen compared to controls exposed to saline. Finally, neonatal rats exposed to 60 mg/kg acetaminophen had dramatically more acetaminophen-Cys adduct in the brain and in liver than did fetal rats (embryonic day 17 and 18) exposed to the same dose of acetaminophen. These results indicate a unique sensitivity of the neonatal rat brain to acetaminophen-mediated toxicity which is not observed in utero.
- 14 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessVulnerability of the Neonatal Rat Brain to Sub-Hepatotoxic Doses of Acetaminophen and Evidence for Fetal Protection
Numerous studies in laboratory animal models have demonstrated that exposure to acetaminophen in utero or in the first days of life leads to long-term alterations in behavior. However, it remains unknown whether acetaminophen metabolism affects the developing brain. Acetaminophen metabolism is characterized by formation of the toxic metabolite, N-acetyl-p-benzoquinone imine, which binds covalently to cysteine residues, forming an adduct and leading to toxicity. In this study, laboratory rats were exposed to 4 doses of acetaminophen over a 2-day period, and tissues were examined two hours following the final exposure. Acetaminophen-Cys adducts were formed in a dose-dependent fashion in the brain of neonatal rats (postnatal days 4 and 5) exposed to 30 mg/kg, 60 mg/kg, and 150 mg/kg acetaminophen. Based on immunohistochemical assessment of cleaved caspase-3 and the formation of pyknotic bodies, higher levels of cell death in the prefrontal cortex and the nucleus accumbens were observed in neonates treated with 60 mg/kg and 150 mg/kg acetaminophen compared to controls exposed to saline. Finally, neonatal rats exposed to 60 mg/kg acetaminophen had dramatically more acetaminophen-Cys adduct in the brain and in liver than did fetal rats (embryonic day 17 and 18) exposed to the same dose of acetaminophen. These results indicate a unique sensitivity of the neonatal rat brain to acetaminophen-mediated toxicity which is not observed in utero.
- Open Access
- 17 September 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1334
Isolation of Hymenolepis diminuta cysticercoids for therapeutic use: The need for fully disclosed methodology
Background Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. Methods The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm 2 , dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. Conclusions This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.
- 17 September 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1334
Open AccessIsolation of Hymenolepis diminuta cysticercoids for therapeutic use: The need for fully disclosed methodology
Background Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. Methods The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm 2 , dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. Conclusions This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.
- Open Access
- 7 September 2026
- Published by MDPI AG in Preprints.org
Considering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- 7 September 2026
- Published by MDPI AG in Preprints.org
Open AccessConsidering the Acetaminophen/Autism Connection in the Light of New Evidence
Numerous lines of evidence have previously allowed us to conclude that exposure of susceptible individuals to acetaminophen triggers many if not most cases of autism spectrum disorders (ASD), which have steadily increased in the US since 1980. Reasons for increasing acetaminophen exposure early in life include the switch from aspirin to acetaminophen in the early 1980s, dramatically increased marketing of acetaminophen in the 1990s, the development of acetaminophen use for opioid sparing protocols in response to the opioid crisis of the 2010s, and continued use of acetaminophen for vaccination as the vaccine schedule increased between 1980 and the present time. More recently, two sets of data from the US, one from the California Public School system and another from the NIH-sponsored ECHO study, indicate that the prevalence of autism spectrum disorders (ASD) is increasing dramatically in a manner dependent on low socioeconomic status. Some evidence suggests that a potential adverse drug-drug interaction between acetaminophen and cannabis use disorder may underlie this trend, with an increase in cannabis use disorder resulting from the legalization of recreational cannabis use. Although increasing use of acetaminophen and potentially changing environmental factors that enhance acetaminophen toxicity can explain the sustained rise in ASD, data consistent with the acetaminophen/autism model continue to be misinterpreted by those considered experts in the field, hampering progress. Most errors involve over-correction for mediating factors in large sibling-controlled studies, although more recent data involving socioeconomic-dependent disparities in ASD prevalence have also been misinterpreted.
- Open Access
- 8 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1334
Isolation of Hymenolepis diminuta cysticercoids for therapeutic use: The need for open-source methodology
Background Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. Methods The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm 2 , dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. Conclusions This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.
- 8 August 2026
- Published by F1000 Research Ltd in F1000Research
- Vol. 15, 1334
Open AccessIsolation of Hymenolepis diminuta cysticercoids for therapeutic use: The need for open-source methodology
Background Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. Methods The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. Results The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm 2 , dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. Conclusions This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics.
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
An Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessAn Update on the Connection Between Acetaminophen and Autism: Expanding Evidence and Misinterpreted Sibling Control Studies
More than 30 lines of discrete, independent evidence implicate the exposure of susceptible babies and children to acetaminophen with the etiology of autism spectrum disorder (ASD). The most abundant source of evidence is from the fields of pharmacology and toxicology, with clinical and epidemiological observations, numerous miscellaneous observations, and studies in laboratory animal models providing conclusive support. This narrative review summarizes that evidence, and discusses recent work with sibling control analysis that has been unfortunately misinterpreted as a result of incorrect assignment of interacting variables as confounding factors. Susceptibility to acetaminophen-induced injury is imposed by a range of genetic, epigenetic, and environmental factors associated with oxidative stress, and is apparently the greatest immediately after birth. Susceptibility then decreases until about six years of age, which is outside of the developmental window in which regression into ASD typically occurs. Although associations between heavy use of acetaminophen during pregnancy and ASD suggest some risk may be present during pregnancy, insufficient evidence is available to know if sporadic use of acetaminophen during pregnancy poses any risks. Given continued use of acetaminophen during labor and delivery, and routine use during early childhood including for indications including circumcision, vaccination, and some chronic medical conditions, a course correction in clinical practice is much needed.
- Open Access
- 9 April 2026
- Published by MDPI AG in Preprints.org
Hypothesis: Emerging Evidence Might Suggest That Increases in Cannabis Use Disorder Following Legalization of Recreational Cannabis Significantly Contribute to Socioeconomic-Dependent Increases in the Prevalence of Autism Spectrum Disorder
A recent report on the prevalence of autism spectrum disorder (ASD) from California describes unprecedented levels of ASD in that population. The data indicate a transition or changepoint in 2015-2016 in which the prevalence of ASD began to accelerate more rapidly after almost a decade of consistent yearly increases. The changepoint is associated strongly with socioeconomic status, being most readily observable in black children and in low-income counties. Herein we propose the hypothesis that legalization of recreational cannabis in late 2016 led to several cultural changes that in turn caused socioeconomic-dependent increases in very frequent cannabis use and/or cannabis use disorder (CUD). CUD is strongly associated with ASD, and we hypothesize that an adverse drug-drug interaction between acetaminophen and a component or components of cannabis may be at play. It remains unknown whether prenatal or postnatal exposures may be more critical, and further work aimed at evaluating very frequent cannabis use and/or CUD and ASD rates in subsets of the population is strongly encouraged. Paradoxically, caution is urged so that work to decrease CUD does not impede ongoing and promising work using cannabis and cannabis-derived products for the treatment of patients with ASD.
- 9 April 2026
- Published by MDPI AG in Preprints.org
Open AccessHypothesis: Emerging Evidence Might Suggest That Increases in Cannabis Use Disorder Following Legalization of Recreational Cannabis Significantly Contribute to Socioeconomic-Dependent Increases in the Prevalence of Autism Spectrum Disorder
A recent report on the prevalence of autism spectrum disorder (ASD) from California describes unprecedented levels of ASD in that population. The data indicate a transition or changepoint in 2015-2016 in which the prevalence of ASD began to accelerate more rapidly after almost a decade of consistent yearly increases. The changepoint is associated strongly with socioeconomic status, being most readily observable in black children and in low-income counties. Herein we propose the hypothesis that legalization of recreational cannabis in late 2016 led to several cultural changes that in turn caused socioeconomic-dependent increases in very frequent cannabis use and/or cannabis use disorder (CUD). CUD is strongly associated with ASD, and we hypothesize that an adverse drug-drug interaction between acetaminophen and a component or components of cannabis may be at play. It remains unknown whether prenatal or postnatal exposures may be more critical, and further work aimed at evaluating very frequent cannabis use and/or CUD and ASD rates in subsets of the population is strongly encouraged. Paradoxically, caution is urged so that work to decrease CUD does not impede ongoing and promising work using cannabis and cannabis-derived products for the treatment of patients with ASD.
- Open Access
- 1 August 2025
- Published by MDPI AG in Preprints.org
Evidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade
Overwhelming evidence shows that exposure of susceptible babies and children to acetaminophen (paracetamol) triggers many if not most cases of autism spectrum disorder, and that oxidative stress causes susceptibility. However, these conclusions have not yet been widely acknowledged or integrated into clinical practice or regulatory guidelines, leaving the continued high prevalence of autism spectrum disorder unchecked. To understand why the conclusions have not been widely accepted, this study conducts systematic analyses of all PubMed-indexed papers with “acetaminophen” and “autism” in any search field. In these papers, statements that failed to promote changes in clinical practice or regulatory guidelines were pervasive. Also pervasive were mishandlings of available evidence, including treating interacting variables as if they are confounding factors (66% of studies affected) and considering too narrow a range of evidence (77% of studies affected). Also present were erroneous criticisms of potentially groundbreaking research, undermining the potential impact of that research. It is hoped that identification of these fundamental problems will lead to widespread acceptance of the evidence that acetaminophen triggers autism spectrum disorder in susceptible babies and children and to subsequent regulatory and clinical changes that will effectively and quickly reduce the induction of autism spectrum disorder.
- 1 August 2025
- Published by MDPI AG in Preprints.org
Open AccessEvidence That Acetaminophen Triggers Autism in Susceptible Individuals Has Been Ignored and Mishandled for More than a Decade
Overwhelming evidence shows that exposure of susceptible babies and children to acetaminophen (paracetamol) triggers many if not most cases of autism spectrum disorder, and that oxidative stress causes susceptibility. However, these conclusions have not yet been widely acknowledged or integrated into clinical practice or regulatory guidelines, leaving the continued high prevalence of autism spectrum disorder unchecked. To understand why the conclusions have not been widely accepted, this study conducts systematic analyses of all PubMed-indexed papers with “acetaminophen” and “autism” in any search field. In these papers, statements that failed to promote changes in clinical practice or regulatory guidelines were pervasive. Also pervasive were mishandlings of available evidence, including treating interacting variables as if they are confounding factors (66% of studies affected) and considering too narrow a range of evidence (77% of studies affected). Also present were erroneous criticisms of potentially groundbreaking research, undermining the potential impact of that research. It is hoped that identification of these fundamental problems will lead to widespread acceptance of the evidence that acetaminophen triggers autism spectrum disorder in susceptible babies and children and to subsequent regulatory and clinical changes that will effectively and quickly reduce the induction of autism spectrum disorder.
- Open Access
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Isolation of Hymenolepis diminuta Cysticercoids for therapeutic use: The need for open-source methodology (Preprint)
BACKGROUND Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. OBJECTIVE This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. METHODS The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. RESULTS The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm2, dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. CONCLUSIONS This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics. CLINICALTRIAL Not applicable
- 23 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessIsolation of Hymenolepis diminuta Cysticercoids for therapeutic use: The need for open-source methodology (Preprint)
BACKGROUND Helminth therapy holds considerable theoretical promise for clinical and public health applications. Unfortunately, clinical trials have often used helminths produced using methods that are both highly variable and insufficiently described in the literature, which may hinder reproducibility and troubleshooting. OBJECTIVE This study aimed to devise a method for purification of helminths that avoids mechanical filtration, which may damage some organisms. In particular, the goal was to devise a method to separate large quantities of cysticercoids of the cestode species Hymenolepis diminuta (HDCs), a process that has not been described previously but that would be necessary before HDCs can be used clinically. METHODS The physical size and behavior of HDCs in solution were assessed and used to create a patented washing device. RESULTS The cross-sectional area of HDCs varied over a 10-fold range, from approximately 0.06 to 0.6 mm2, dependent in large part upon the host. That cross-sectional area correlated in a linear fashion with the steady-state speed of HDCs while falling through solution, which varied over a 5-fold range, from approximately 0.4 mm/s to 2.0 mm/s in the solution tested. These parameters were used to develop a washing device that utilized a variable flow speed dictated by changing column diameter and an upward flowing column of liquid that effectively and simultaneously suspended HDCs of various sizes in a wash solution. CONCLUSIONS This study describes a detailed method of purification of HDCs, organisms that could potentially be used for helminth therapy. It is hoped that government agencies or non-profit organizations can use such technology to conduct rigorous clinical trials, potentially leading to the production of reasonably priced therapeutics. CLINICALTRIAL Not applicable
- Open Access
Evaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism Spectrum Disorder
More than 20 previously reported lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to the aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in silico methods to create an ideal (virtual) population of 120,000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal dataset shows little to no risk of acetaminophen use if the cofactors that create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors that impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in the analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
Open AccessEvaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism Spectrum Disorder
More than 20 previously reported lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to the aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in silico methods to create an ideal (virtual) population of 120,000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal dataset shows little to no risk of acetaminophen use if the cofactors that create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors that impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in the analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
- Open Access
- 4 June 2024
- Published by MDPI AG in Preprints.org
Evaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism
More than 20 lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations previously indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in-silico methods to create an ideal (virtual) population of 120000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal data set shows little to no risk of acetaminophen use if cofactors which create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors which impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.
- 4 June 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluating the Role of Susceptibility Inducing Cofactors and of Acetaminophen in the Etiology of Autism
More than 20 lines of independent evidence from clinical observations, studies in laboratory animal models, pharmacokinetic considerations, and numerous temporal and spatial associations previously indicate that numerous genetic and environmental factors leading to inflammation and oxidative stress confer vulnerability to aberrant metabolism of acetaminophen during early development, leading to autism spectrum disorder (ASD). Contrary to this conclusion, multivariate analyses of cohort data adjusting for inflammation-associated factors have tended to show little to no risk of acetaminophen use for neurodevelopment. To resolve this discrepancy, here we use in-silico methods to create an ideal (virtual) population of 120000 individuals in which 50% of all cases of virtual ASD are induced by oxidative stress-associated cofactors and acetaminophen use. We demonstrate that Cox regression analysis of this ideal data set shows little to no risk of acetaminophen use if cofactors which create aberrant metabolism of acetaminophen are adjusted for in the analysis. Further, under-reporting of acetaminophen use is shown to be a considerable problem for this analysis, leading to large and erroneously low calculated risks of acetaminophen use. In addition, we argue that factors which impart susceptibility to acetaminophen-induced injury, and propensity for acetaminophen use itself, can be shared between the prepartum, peripartum, and postpartum periods, creating additional difficulty in analysis of existing datasets to determine risks of acetaminophen exposure for neurodevelopment during a specific time frame. It is concluded that risks of acetaminophen use for neurodevelopment obtained from multivariate analysis of cohort data depend on underlying assumptions in the analyses, and that other evidence, both abundant and robust, demonstrate the critical role of acetaminophen in the etiology of ASD.